Adverse events and complications associated with intravitreal injection of anti-VEGF agents: A review of literature

K. Ghasemi Falavarjani, Q. D. Nguyen

Research output: Contribution to journalReview article

231 Citations (Scopus)

Abstract

Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is increasingly used for the treatment of a wide variety of retinal diseases, including age-related macular degeneration, diabetic retinopathy and retinal vascular occlusions, and retinopathy of prematurity. Despite encouraging results in halting the disease and improving the vision, intravitreal injection of anti-VEGF agents may be associated with systemic adverse events and devastating ocular complications. In this review, we provide an overview of safety data for intravitreal injection of common anti-VEGF agents.

Original languageEnglish (US)
Pages (from-to)787-794
Number of pages8
JournalEye (Basingstoke)
Volume27
Issue number7
DOIs
StatePublished - May 31 2013

Fingerprint

Intravitreal Injections
Vascular Endothelial Growth Factor A
Retinal Diseases
Retinal Vessels
Retinopathy of Prematurity
Macular Degeneration
Diabetic Retinopathy
Safety
Therapeutics

Keywords

  • Aflibercept
  • Anti-vascular endothelial growth factor
  • Bevacizumab
  • Intravitreal injection
  • Ranibizumab
  • Safety

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems

Cite this

Adverse events and complications associated with intravitreal injection of anti-VEGF agents : A review of literature. / Falavarjani, K. Ghasemi; Nguyen, Q. D.

In: Eye (Basingstoke), Vol. 27, No. 7, 31.05.2013, p. 787-794.

Research output: Contribution to journalReview article

@article{276e2a5569a04a27b9dccd9c830e50c7,
title = "Adverse events and complications associated with intravitreal injection of anti-VEGF agents: A review of literature",
abstract = "Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is increasingly used for the treatment of a wide variety of retinal diseases, including age-related macular degeneration, diabetic retinopathy and retinal vascular occlusions, and retinopathy of prematurity. Despite encouraging results in halting the disease and improving the vision, intravitreal injection of anti-VEGF agents may be associated with systemic adverse events and devastating ocular complications. In this review, we provide an overview of safety data for intravitreal injection of common anti-VEGF agents.",
keywords = "Aflibercept, Anti-vascular endothelial growth factor, Bevacizumab, Intravitreal injection, Ranibizumab, Safety",
author = "Falavarjani, {K. Ghasemi} and Nguyen, {Q. D.}",
year = "2013",
month = "5",
day = "31",
doi = "10.1038/eye.2013.107",
language = "English (US)",
volume = "27",
pages = "787--794",
journal = "Eye (London, England)",
issn = "0950-222X",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Adverse events and complications associated with intravitreal injection of anti-VEGF agents

T2 - A review of literature

AU - Falavarjani, K. Ghasemi

AU - Nguyen, Q. D.

PY - 2013/5/31

Y1 - 2013/5/31

N2 - Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is increasingly used for the treatment of a wide variety of retinal diseases, including age-related macular degeneration, diabetic retinopathy and retinal vascular occlusions, and retinopathy of prematurity. Despite encouraging results in halting the disease and improving the vision, intravitreal injection of anti-VEGF agents may be associated with systemic adverse events and devastating ocular complications. In this review, we provide an overview of safety data for intravitreal injection of common anti-VEGF agents.

AB - Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is increasingly used for the treatment of a wide variety of retinal diseases, including age-related macular degeneration, diabetic retinopathy and retinal vascular occlusions, and retinopathy of prematurity. Despite encouraging results in halting the disease and improving the vision, intravitreal injection of anti-VEGF agents may be associated with systemic adverse events and devastating ocular complications. In this review, we provide an overview of safety data for intravitreal injection of common anti-VEGF agents.

KW - Aflibercept

KW - Anti-vascular endothelial growth factor

KW - Bevacizumab

KW - Intravitreal injection

KW - Ranibizumab

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=84880268774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880268774&partnerID=8YFLogxK

U2 - 10.1038/eye.2013.107

DO - 10.1038/eye.2013.107

M3 - Review article

C2 - 23722722

AN - SCOPUS:84880268774

VL - 27

SP - 787

EP - 794

JO - Eye (London, England)

JF - Eye (London, England)

SN - 0950-222X

IS - 7

ER -